Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias
"This technology marks a significant advancement in how we care for patients with heart rhythm disorders—particularly those who previously had few viable cardiac resynchronization therapy treatment options," said Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI. "At the Texas Cardiac Arrhythmia Institute, our commitment is to bring the most advanced, evidence-based therapies to patients worldwide, and as a result of Dr. Canby's leadership, we successfully delivered on that promise."
The system is the first-ever to stimulate the heart muscle electrically via a small, leadless device—about the size of a grain of rice—that is implanted inside tissue of the left ventricle, the heart's primary pumping chamber. The device converts ultrasound energy into electrical pulses, restoring the heart's normal rhythm and pumping efficiency.
Traditional cardiac resynchronization therapies involve leads—thin and soft insulated wires about the size of a spaghetti noodle. This left ventricular endocardial pacing device provides a direct approach, which enables more flexible placement and expands access to those who were previously considered untreatable.
TCAI is a state-of-the-art Electrophysiology Center that includes six labs equipped with advanced technology where a group of esteemed cardiac electrophysiologists—led by Dr. Natale, a world-renowned expert in the field—perform a high volume of the most complex electrophysiology procedures.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
2 days ago
- Korea Herald
Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint
SUZHOU, China, July 26, 2025 /PRNewswire/ -- The Kintor Pharmaceutical Limited (the " Company") is pleased to announce that the Phase II Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of AGA has obtained top-line results. Results indicated that the Phase II Stage has reached its primary endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent efficacy and safety. Analysis results of the 90 patients enrolled in the Phase II Stage showed that: The hair growth assessment (" HGA") indicators from investigators of 0.5% BID group and 1.0% BID group both experienced significant improvement from placebo group, with a significant therapeutic effect. The results showed that after the treatment of 24 weeks, compared to the placebo group, the HGA indicator of the 0.5% BID group displayed statistically significant results (P=0.000); compared to the placebo group, the HGA indicator of the 1.0% BID group displayed statistically significant results (P=0.013). The analysis results were reviewed by the Independent Data Monitoring Committee (IDMC), and its primary recommendation was that the Phase III Stage clinical trial should continue based on the current safety and efficacy data, with no modifications to treatment group or sample size.
Korea Herald
3 days ago
- Korea Herald
AMSC Malaysia 2025 Set to Spotlight World-Class Expertise and Innovation in Aesthetic Medicine and Surgery
KUALA LUMPUR, Malaysia, July 24, 2025 /PRNewswire/ -- The Aesthetic Medicine & Surgery Conference & Exhibition (AMSC) returns for its fourth edition from August 6-7, 2025, with an expanded focus on global participation and advanced education. Held at the Kuala Lumpur Convention Centre (KLCC), AMSC 2025 will feature over 160 world-class speakers, 200 international brands, and 20 supporting partners, including 13 medical societies and 7 industry collaborators. More than 1,600 delegates from around the world are expected, with highlights including clinical innovation updates, live demonstrations, and expert insights from speakers representing over 30 countries. "AMSC Malaysia 2025 represents a global crossroads for aesthetic medicine, where regional insights meet international expertise. This year, we are not just sharing techniques, we are also building a collaborative future for the field by fostering dialogue, discovery, and innovation across borders," said Dr Tingsong Lim, President of the Malaysian Society of Aesthetic Medicine (MSAM) and Scientific Director of AMSC. Elevating Aesthetic and Regenerative Care for Diverse Needs AMSC Malaysia 2025 will explore a wide range of cutting-edge topics in aesthetic and regenerative medicine. These include Periorbital Rejuvenation, focusing on advanced techniques using fillers, threads, and devices to treat tear troughs and under-eye ageing; Melasma Management, with evidence-based protocols combining lasers, topicals, and regenerative treatments tailored for Asian skin; Facelift Techniques, covering both surgical and non-invasive approaches such as thread lifts, energy-based tightening, and facial sculpting; Longevity Medicine, exploring anti-ageing strategies that utilise semaglutide, hormones, peptides, and polydeoxyribonucleotides (PDRN); Regenerative Aesthetics, highlighting the use of exosomes, stem cells, and PRP to restore skin quality and stimulate collagen; Scar Treatment, featuring multi-modal solutions using lasers, injectables, and biostimulators for acne scars and post-surgical healing; and more. Through these sessions, delegates will gain in-depth knowledge of current clinical trends, master advanced injection and device-based techniques, and learn how to apply combination approaches for improved patient outcomes. The conference provides ample opportunities for attendees to explore innovations in regenerative medicine, deepen their understanding of tailored treatments for diverse skin types and enhance their ability to meet the growing demands of specialised patient segments, including male aesthetics and ageing populations. This year's AMSC welcomes a distinguished line-up of global experts who are redefining the standards of aesthetic and regenerative medicine: The PINOKIO Surgical Zone Returns with Expanded Hands-On Training Returning for its eighth edition in Malaysia, the PINOKIO Surgical Zone at AMSC 2025 brings back Korea's leading surgical organisation for an expanded three-day programme from 6 to 8 August 2025. In a groundbreaking collaboration, AMSC partners with the Plastic Innovative Nasal Ormaxillofacial Korean International Organisation (PINOKIO) to deliver an immersive and focused surgical education experience tailored for professionals seeking to refine their techniques and deepen their anatomical understanding. The agenda includes Day 1: Nose Surgery Focus, Day 2: Face and Chest Lift Techniques, and Day 3: Hands-on Cadaver Masterclass on Rhinoplasty and Surgical Facelift. Delegates will benefit from expert-led lectures, live cadaver dissections, and practical demonstrations guided by some of Asia's most respected surgeons. Additionally, the zone features a curated exhibition showcasing the latest tools and innovations in facial, nasal, and chest aesthetic surgery. Additionally, the exhibition hall will feature leading global brands such as Merz Aesthetics, Juvederm, Skinvive, Neauvia, Oligio, Gouri, Karisma, Multifrax, Sinclair, and Plinest, offering delegates hands-on access to the latest innovations in injectables, energy-based devices, and regenerative solutions.
Korea Herald
4 days ago
- Korea Herald
Seegene unveils the world's first unattended PCR automation, igniting a global diagnostic paradigm shift at ADLM 2025
SEOUL, South Korea, July 23, 2025 /PRNewswire/ -- Seegene Inc., a global leader in molecular diagnostics, announced today that it will unveil its fully automated PCR testing system, CURECA™, and its data analytics platform, STAgora™, at ADLM 2025 (Association for Diagnostics & Laboratory Medicine), the world's largest diagnostics conference, taking place in Chicago from July 28 to 31. With the introduction of these new technologies, Seegene declares a transformative shift in the global diagnostics paradigm. Automating every step of PCR Testing for enhanced efficiency and accuracy CURECA™ is the world's first system to fully automate the entire PCR testing process – from specimen storage and pre-treatment to nucleic acid extraction, amplification, and result analysis – without any human intervention. Designed for 24/7 continuous operation, the system minimizes human error and dramatically improves the consistency and reliability of the test results. A key breakthrough lies in its fully automated prep module, which addresses one of the most burdensome and error-prone stages in diagnostic workflows. Pre-treatment has traditionally been a major challenge, particularly when dealing with diverse sample types such as urine, blood, sputum, and stool. Lab technicians often carry out repetitive manual tasks over extended hours, and variations in skill level can result in inconsistent outcomes. Stool samples, especially, have posed serious automation barriers due to their viscosity and particulates, requiring heavy manual handling. The prep module of CURECA™ system is the first to fully automate pre-treatment process across all major specimen types – including stool – overcoming longstanding obstacles in laboratory operations. This innovation reduces labor demands, expands sample throughput, and enhances overall operational and cost efficiency. It also shifts the role of laboratory personnel from manual processing to higher-level responsibilities, such as data analysis and clinical interpretation – helping labs better leverage their workforce in high-volume testing environments. In addition, the prep module is applicable beyond PCR diagnostics. It supports pre-treatment for other disciplines, including clinical chemistry and immunoassays, marking a significant step forward in automation across the broader diagnostics market. Its modular architecture allows for flexible configuration and deployment tailored to the size, layout, and needs of each laboratory. STAogra ™ – Real-Time Global Data Integration Empowering Personalized Care Also unveiled at ADLM 2025, STAgora™ is Seegene's statistical platform that collects and analyzes real-time PCR diagnostic data to support clinical decision-making. By aggregating test data uploaded from hospitals around the world, the platform provides integrated insights into regional infection trends, hospital-level positivity rates, and patterns of co-infection. It also offers more than 40 statistical tools tailored for clinical support. With STAgora™, healthcare providers can compare individual patient test results with local and regional epidemiological data, enabling more precise, data-driven treatment strategies. The platform allows clinicians to evaluate infection trends at both patient and community levels, improving the accuracy and speed of diagnosis and care planning. By delivering rapid, reliable insights through this kind of comprehensive analysis, STAgora™ is expected to become an essential analytical tool for clinical decision-making. Expanding Global Collaboration via Technology Sharing and Strategic Partnerships Building on its presence at ADLM 2025, Seegene aims to broaden access to CURECA™ and STAgora™ by offering early pilot experiences and establishing new global partnerships. Earlier this year, CURECA™ attracted strong interest at ESCMID Global 2025, one of Europe's leading clinical microbiology and infectious disease congresses. To strengthen its R&D and manufacturing capacity in the United States, Seegene has established local subsidiaries, including Seegene Technologies and Seegene CURECA. "CURECA™ and STAgora™ are more than just diagnostics equipment or software—they represent a new global standard that will redefine diagnostics in clinical settings around the world. We will continue to share the many technological assets we've built over the years and based on this foundation, we are committed to driving fundamental innovation across the global diagnostics ecosystem." Said Daniel Shin, Executive Vice President, Chief of Global Sales & Marketing at Seegene. Disclaimer The product is currently in a pre-commercialization phase. The configuration presented at ADLM 2025 is for demonstration purposes only and may differ in functionality, specifications, and components from the final commercial version. This material is intended solely to introduce the technology and does not constitute an advertisement for product sales. About Seegene Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene's syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar signs and symptoms in a single tube with quantitative information.
